Committee Recommends J&J's (JNJ) ZYTIGA Study Be Unblinded Amid Better Survival Data
Tweet
Share
E-mailGet Alerts JNJ Hot Sheet
Join SI Premium – FREE
J&J's (NYSE: JNJ) Janssen Research & Development, LLC today announced that it has unblinded the Phase 3 study of ZYTIGA® (abiraterone acetate) plus prednisone for the treatment of asymptomatic or mildly symptomatic patients with metastatic castration-resistant prostate cancer (CRPC) who have not received chemotherapy.
Study COU-AA-302 is an international, randomized, double-blind, placebo controlled study that included 1,088 patients who were randomized to receive ZYTIGA 1,000 milligrams (mg) administered once daily plus prednisone 5 mg administered twice daily or placebo plus prednisone 5 mg administered twice daily. The co-primary endpoints of the study are radiographic progression-free survival and overall survival.
The Independent Data Monitoring Committee (IDMC) unanimously recommended unblinding the study based on a planned interim analysis in which differences in radiographic progression-free survival, overall survival, and secondary endpoints were observed that constitute evidence of clinical benefit as well as continued evidence of favorable safety in patients receiving abiraterone acetate plus prednisone as compared to those receiving placebo plus prednisone. Based on these results, the IDMC also recommended that patients in the placebo arm be offered treatment with ZYTIGA.
These results will be presented at an upcoming medical meeting and will also be submitted for publication in a peer-reviewed journal.
Janssen Research & Development is part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
Study COU-AA-302 is an international, randomized, double-blind, placebo controlled study that included 1,088 patients who were randomized to receive ZYTIGA 1,000 milligrams (mg) administered once daily plus prednisone 5 mg administered twice daily or placebo plus prednisone 5 mg administered twice daily. The co-primary endpoints of the study are radiographic progression-free survival and overall survival.
The Independent Data Monitoring Committee (IDMC) unanimously recommended unblinding the study based on a planned interim analysis in which differences in radiographic progression-free survival, overall survival, and secondary endpoints were observed that constitute evidence of clinical benefit as well as continued evidence of favorable safety in patients receiving abiraterone acetate plus prednisone as compared to those receiving placebo plus prednisone. Based on these results, the IDMC also recommended that patients in the placebo arm be offered treatment with ZYTIGA.
These results will be presented at an upcoming medical meeting and will also be submitted for publication in a peer-reviewed journal.
Janssen Research & Development is part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- Elroy Air wins $46M U.S. Army contract for cargo drone system
- Nu Skin EVP of global sales takes medical leave
Create E-mail Alert Related Categories
Corporate News, FDA, Hot FDA NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
